Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ascendra
- Development stage
- Unknown
- Lead developer
- anwerina Deutschland
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Intranasal
01
Overview
Ascendra is an intranasal powder formulation of teriparatide, a recombinant human parathyroid hormone (PTH 1-34), developed by the Japanese biotechnology company Anwerina. It is primarily indicated for the treatment of osteoporosis. As an anabolic bone agent, teriparatide works by binding to and activating the parathyroid hormone receptor 1 (PTH1R), which stimulates osteoblast activity and increases bone formation. Ascendra is designed to provide a non-invasive alternative to the standard subcutaneous injections of teriparatide, potentially enhancing patient adherence and convenience through its nasal delivery system.
- Brand names
- Ascendra
- Other names
- teriparatide nasal powder
02
Targets
PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)
Beyond the preview
Go deeper on Ascendra.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ascendra.